Clinical trials: Schizophrenia, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Schizophrenia
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder)
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3
In Study 3, all tasks and models from Aim 1 will be evaluated in a large community sample of online participants recruited through Prolific.
- Conditions
- Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder), Healthy Adult
- Trial name
- CNTRACS (NCT07900893)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 2 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia Disorders
The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.
Study to evaluate the safety and tolerability of single ascending doses of brexpiprazole long-acting injection in healthy subjects/patients with schizophrenia.
- Trial name
- NCT06674694
- Testing
- Brexpiprazole long-acting injection
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Sichuan Kelun Pharmaceutical Co.,Ltd.
Schizophrenia Disorder, Schizoaffective Disorder
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
This study is a randomized controlled trial evaluating the impact of financial incentives on medication adherence among individuals with schizophrenia, schizoaffective disorder, or bipolar disorder and/or co-occurring substance…
- Conditions
- Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD), Substance Use Disorder (SUD)
- Trial name
- NCT07130500
- Testing
- Financial incentives for adherence to long-acting injectable medication, Standard of care with monthly surveys
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Stanford University
Schizophrenia
Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia
To evaluate the efficacy of Paliperidone Palmitate Injection in replacing oral antipsychotics for the treatment of schizophrenia and its impact on social function
- Trial name
- NCT07075237
- Testing
- Paliperidone Palmitate Injection (PP1M)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
In Study 1, investigators will test the ability of each of the seven paradigms to differentiate between schizophrenia (SZ)/schizoaffective disorder (SZA) and matched healthy control subjects (HC) and to predict individual…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder, Healthy Adult Participants
- Trial name
- CNTRACS (NCT07853807)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 5 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.
- Trial name
- NCT07680946
- Testing
- Ublituximab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- TG Therapeutics, Inc.
Schizophrenia
Phase I Trial of HHK101 in Patients With Schizophrenia
This study aims to learn how the study drug is absorbed by the body, check for possible side effects, and see if the drug may help improve symptoms in patients with schizophrenia.
- Trial name
- NCT07815210
- Testing
- HHK101-Single Dose 1, HHK101-Single Dose 2, HHK101-Single Dose 3
- Where
- 4 sites in China
- Volunteers
- 88 people
- Sponsor
- Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Schizophrenia
Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia.
The primary objective of this study is to evaluate the bioequivalence of aripiprazole for injection (Test product, 400 mg) compared with Abilify Maintena® (Reference product, 400 mg) at steady state in patients with…
- Trial name
- NCT07547384
- Testing
- Aripiprazole for Injection
- Volunteers
- 116 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Schizophrenia
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia
- Trial name
- NCT07061288
- Testing
- KarXT
- Where
- 8 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bristol-Myers Squibb
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2
In Study 2, investigators will recruit individuals with schizophrenia (SZ) and or schizoaffective disorder (SZA) and healthy controls (HC) using optimized behavioral tasks to replicate the behavioral findings from Study 1 and to…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder, Healthy Adult
- Trial name
- CNTRACS 2 (NCT07875790)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 5 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophrenia
This study is to evaluate the pharmacokinetics (PK), safety and tolerability of Brexpiprazole, administered subcutaneously, in subjects with schizophrenia.
- Trial name
- NCT07742280
- Testing
- Brexpiprazole for ER injection, 45 mg, Brexpiprazole for ER injection, 100 mg
- Volunteers
- 16 people
- Sponsor
- Bostal Drug Delivery Co., Ltd
First Episode Psychosis (FEP)
Dopamine and Insulin in Psychosis
Patients with schizophrenia have a high risk of developing metabolic disorders and current evidence points to an overlap in mechanisms underlying psychiatric symptoms and metabolic disturbances.
- Trial name
- DIPS (NCT07252752)
- Testing
- Intranasal Insulin, Low dose insulin infusion, [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
- Where
- Austria
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Treatment-resistant Schizophrenia
Sequential Treatment Approaches for Treatment-Resistant Schizophrenia
The goal of this study is to optimize treatment strategies for Chinese patients with treatment-resistant schizophrenia (TRS). It will compare two types of treatment: 1.
- Trial name
- STATRS (NCT07918222)
- Testing
- [Phase 1] Clozapine, [Phase 1] Aripiprazole, [Phase 1] Amisulpride
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AX251 long-acting injectable (LAI) administered as a single dose in patients with schizophrenia.
- Trial name
- NCT07484204
- Testing
- AX251 LAI 45 mg, AX251 LAI 90 mg, AX251 LAI 135 mg
- Where
- 4 sites in India
- Volunteers
- 48 people
- Sponsor
- Anxo Pharmaceutical Co., Ltd.
Schizophrenia, Schizo Affective Disorder
Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia
This 16 week clinical trial investigates a precision-medicine approach to schizophrenia by targeting a biologically distinct subgroup,-approximately one-third of patients-characterized by the presence of anti-gliadin antibodies…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Healthy
- Trial name
- NCT07615075
- Testing
- IL-23
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Bipolar I Disorder
Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
The purpose of this study is to assess the PK, Safety, Tolerability (all cohorts) and Efficacy (cohort 3), of once-a-month long-acting SC injection of dose escalating Cariprazine Depot in subjects eligible for treatment with oral…
- Conditions
- Schizophrenia, Bipolar I Disorder, Major Depressive Disorder
- Trial name
- NCT07185815
- Testing
- Cariprazine Depot, Cariprazine Depot MTD, Oral Cariprazine 3 mg/day
- Where
- 6 sites in India, Israel
- Volunteers
- 24 people
- Sponsor
- Mapi Pharma Ltd.
Schizophrenia
A Bioequivalence Study of PP3M in Patients With Schizophrenia
To evaluate the bioequivalence of the test formulation paliperidone palmitate injection (3M) produced by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Trial name
- NCT07493551
- Testing
- Paliperidone Palmitate Injection (3M)
- Where
- China
- Volunteers
- 260 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Major Depressive Disorder, Bipolar Disorder
Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT
This prospective, open-label clinical trial aims to compare a novel "Venous Tourniquet with Regional Low-Dose Sugammadex" method against the gold standard "Arterial Tourniquet" (Isolated Forearm Technique - IFT) for monitoring…
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Schizophrenia
- Trial name
- NCT07534475
- Testing
- Device: Arterial Tourniquet, Device: Venous Tourniquet, Sugammadex
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Medipol University
Severe Mental Illness, Depression / Major Depressive Disorder
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
This randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar…
- Conditions
- Severe Mental Illness, Depression / Major Depressive Disorder, Bipolar Disorder (BD), Schizophrenia
- Trial name
- LIFETRAIN (NCT07586150)
- Testing
- Semaglutide (SEMA), Exercise module, Anti-inflammatory diet module
- Where
- 5 sites in Austria, Germany and 1 more
- Volunteers
- 140 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Alcohol Use Disorder, Alcohol Abuse/Dependence
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism
- Trial name
- DUALPSYCHIATRY (NCT06939088)
- Testing
- Tirzepatide
- Where
- 2 sites in Denmark
- Volunteers
- 108 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci